Kangstem Biotech acquires approval of world’s first stem cell treatment for atopic dermatitis

Published: 2017-12-06 15:12:32

Updated: 2017-12-06 15:12:32

Kangstem Biotech(CEO Tae-Hwa Lee) announced on the 5^th that it acquired IND(Investigational New Drug) of a Phase III clinical trial for ‘Furestem-AD,’ the world’s first and only stem cell therapeutic product for atopic dermatitis.

In the Phase III clinical trial, total 194 patients with severe atopic dermatitis will take Furestem-AD or comparison drugs to assess efficacy and safety based on th...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.